Top advances of the year: Acute myeloid leukemia

This article highlights key advances in the treatment of acute myeloid leukemia, specifically menin inhibitors for relapsed disease and retinoic acid/arsenic‐based therapy for high‐risk acute promyelocytic leukemia. Validation of mutational profiles and measurable residual disease methodology as key predictors of treatment outcomes support a personalized, precision‐based treatment approach for acute myeloid leukemia in the future.